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ABSTRACT 
 
Background. Peak cardiac power output (peak CPO) at exercise 
echocardiography showed to be closely related to peak VO2 at 
cardiopulmonary exercise testing (CPET). To gain further perspective in the 
evaluation of left ventricular (LV) remodeling in myocardial hypertrophy, the 
peak cardiac power output-to-LV mass (peak CPOM), a measure of the rate at 
which cardiac work is delivered with respect to the potential energy stored in 
LV mass, was recently introduced.  
Aim. To compare the value of peak CPOM with CPET variables in the 
prognostic stratification of patients with chronic stable heart failure (HF) due 
to LV dysfunction.  
Materials and methods. 115 patients with chronic stable HF (mean LV EF% 
0.31±0.6) underwent CPET and exercise echocardiography. The two tests 
were performed within 7 days according to standard symptom-limited 
exercise protocols. Peak CPOM was calculated as the product of a constant 
(K=2.22 x 10
-1
) with cardiac output (CO) and the mean arterial pressure 
(MAP) divided by LV mass (M) to convert the units to watts/100 g: CPO = K 
 CO (l/min)  MAP (mmHg)  M-1(g). Patients were followed-up for the 
composite end point of all-cause mortality or hospitalization for HF.  
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Results. There were 16 deaths and 21 hospitalizations for worsening HF 
during a mean follow-up of 24 months. At ROC analyses, the areas under the 
curve for the composite end point were greater for peak CPOM (AUC=0.82) 
and VE/VCO2 (AUC=0.76), followed by CPO (AUC=0.75), peakVO2 
predicted (AUC 0.72), VO2 (AUC =0.69), LV EF (AUC=0.69) and NYHA 
class (AUC=0.68). At the multivariate logistic regression analysis, peak 
CPOM was the most powerful predictor of outcome (p <0.0001). The Kaplan-
Meier analysis revealed that survival free from HF-hospitalization at 24 
months was 83% in patients with a peak CPOM >0.60 watts/100 g, while it 
was 29% in those with a peak CPOM ≤0.60 watts/100 g (p <0.0001, Logrank: 
34.1). 
Conclusion. The assessment of LV ratio power-to-mass by the echo-derived 
peak CPOM can provide additional insights in the prognostic stratification of 
patients with HF. 
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1  HEART FAILURE 
 
Over the years many definitions of heart failure (HF) have been given. The 
historically-recognized definition is the one conveyed by Braunwald in his 
essay: “The heart failure is a pathophysiological state, in which an 
abnormality of cardiac function is responsible for the failure of the heart to 
pump blood at a rate commensurate with the requirements of the metabolizing 
tissues, or in which the heart can do it at the expense of an increase of the 
filling pressure. The inability of the heart to satisfy the tissue needs can be 
due to an inefficient or insufficient filling and/or to an abnormal contraction 
and following emptying”.1 The same author defines the heart failure also 
under a clinical point of view as “a syndrome that affects those patients who, 
because of hereditary or acquired alterations of the heart structure or the heart 
function, develop a constellation of clinical symptoms (dyspnoea and 
asthenia) and signs (oedema and wheeze) that lead to frequent 
hospitalizations, to a decrease of the quality of life and to a minor life 
expectancy”.2 When a symptomatology due to an organ dysfunction turns up, 
we can start talking about decompensated heart failure. 
In 2013 AHA guidelines for the Management of Heart Failure, HF is defined 
as “a complex clinical syndrome that results from any structural or functional 
impairment of ventricular filling or ejection of blood”.  
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1.1 Epidemiology 
The heart failure has been defined as an epidemic but its real epidemiology is 
complex because of the several factors that interact in a complicated way to 
influence its prevalence and incidence.
3
 Some manifestations, above all the 
early and the organ-specific ones, can be difficult to diagnose precisely. The 
intrinsic ambiguity led to the definition of various criteria used in 
epidemiological studies, such as the ones used by the Framingham Heart 
Study, those used by Cardiovascular Health Study or by the European Society 
of Cardiology.
4
 
 
Every year 670.000 new cases of heart failure are diagnosed.
5
 Some studies 
have demonstrated how the incidence, adapted for gender and age, has been 
steady in the last years,
6
 whereas the prevalence turns out to be increased 
from the 70s thanks to the increase of survival of the patients affected.
7
 The 
prevalence, specifically, increases with age and in particular it mainly 
enhances over the age of 65. Even though the relative incidence is minor in 
women, they form more than the half of cases due to the superior life 
expectancy. Furthermore the combination between an ageing of the world 
population and a demographic increase will lead to a reduplication of the 
population over 65 years old, so the most exposed category, and consequently 
to a further increase of individuals affected by heart failure.
8
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It is evaluated that there are about 23 millions of people in the world affected 
by heart failure nowadays.
9
 
 
For what concerns the death rate, despite of the improvement of both 
diagnostic techniques and therapeutic options, the heart failure still remains a 
deadly clinical syndrome. According to the Framingham Heart Study, the 
mortality at 30 days increases up to 10%, at a year up to 20-30% and at 5 
years up to 45-60%.
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1.2 Clinical classification 
The heart failure can be functionally divided into: 
 High-output heart failure 
 Low-output heart failure. 
The high-output heart failure is characterized by a volumetric overload, with a 
consequent increase of the ventricular diastolic pressure, but with a stroke 
volume chronically elevated. 
With “high-output” we usually refer to a value > 8 litres/minute o as a cardiac 
index > 3.9 l/min/m
2
.
10
 According to some authors, the same definition would 
be improper because the heart is inherently normal and able to generate a high 
stroke volume; others, instead, have highlighted that, anyhow, it is a condition 
that occurs only with in presence of underlying cardiac illnesses.
11
 A chronic 
high-output condition can be associated to cardiac dilatation and hypertrophy, 
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persistent tachycardia and valvular abnormalities: these are conditions that 
can all culminate into the development of heart failure. From a 
pathophysiological point of view, the main problem in the high-output form is 
linked to the presence of reduced peripheral vascular resistances that are 
caused by a phenomenon of widespread vasodilation or by the presence of an 
arterial-venous shunt. 
Both these conditions can determine a drop in systemic arterial pressure, a 
peculiarity of low-output heart failure. Nonetheless this condition leads to a 
sympathetic activation, to an offsetting increase of the cardiac output and to a 
neurohormonal activation (included RAS and vasopressin); this process may 
cause hydrosaline retention and decompensated heart failure. Therefore the 
hydrosaline retention, that ensues a neurohormonal reaction similar to that in 
the systemic hypotension, occurs in both the low- and high-output, but in the 
first case is due to the reduced cardiac output, while in second one to a 
decrease of the peripheral vascular resistances (see Figure 1.1).
12
 
The main causes of this kind of heart failure include chronic anaemia, 
thyrotoxicosis, presence of a systemic arterio-venous fistula, Paget’s disease.  
In Western countries, the prevalence is much lower if compared to the low-
output heart failure, characterized by a decreased cardiac output. 
 
      
11 
 
 
Figure 1.1 Diagram illustrating the mechanisms by which various pathological conditions can lead to high-
output heart failure.
10
 
 
 
1.3 Aetiology and risk factors 
In recent years, attention has been focused on the distinction between heart 
failure with reduced ejection fraction (HErEF, less than 40%) and heart 
failure with preserved ejection fraction (HEpER, more than 40-50%). In order 
to define the preserved ejection fraction-form, many criteria have been 
proposed, which include: clinical signs and symptoms of heart failure, 
evidence of preserved or normal left ventricular ejection fraction and evidence 
of abnormalities in left ventricle with diastolic dysfunction that can be 
determined by Doppler-echocardiography or cardiac catheterization.
13
 Studies 
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demonstrated that the incidence of HFpEF is increasing and a great portion of 
hospitalized patients shows this variant; they are mainly older women with a 
history of arterial hypertension
14
, but at the base there are frequently obesity, 
CAD, diabetes mellitus, atrial fibrillation, and hyperlipidaemia, as well.
15
 
Patients who show a left ventricular systolic dysfunction typically have some 
elements of diastolic dysfunction.
16
 
 
Despite of the difference between the two aetiologies, there are many points 
in common. In industrialized countries, the main cause (60-75%) of heart 
failure is coronary artery disease, including both ischemia and acute 
myocardial infarction, in both genders. Studies have shown that within 7-8 
years following a myocardial infarction, more than one third of patients will 
develop heart failure, especially those individuals affected by a left 
ventricular dysfunction that had already been detected at the time of the acute 
event.
17
 So having a positive anamnesis for AMI enhances exponentially the 
probability of developing heart failure during life and it is not surprising that, 
given the close association between coronary artery disease and heart failure, 
a lot of atherosclerosis risk factors are also risk factors for the development of 
the second one. 
In the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in 
Hospitalized Patients with Heart Failure) Registry, ischemia was pointed out 
13 
 
as the main cause of hospitalization in patients with heart failure and also the 
principal responsible for hospital death rate in the same patients.
18 
 
Another important risk factor for heart failure is arterial systemic 
hypertension, responsible for the appearance of a pressure overload in the left 
ventricle. In the cohort of patients from the Framingham study, 75% of 
patients had a history of AHT.
19
 In previous studies, it had already been 
highlighted how AHT also doubles the risk of developing heart failure in men 
and even triples in women.
20
 There is a correlation between the magnitude of 
ATH and the risk of the disease since the greater is the elevation of blood 
pressure, the greater the risk of developing heart failure is. The probability of 
fatal events in patients with BP ≥160/90 mmHg is twice that of those with BP 
<140/90 mmHg.
19
 
 
The pressure overload can be equally caused by an obstructive valvular 
disease.
21
  
 
Also diabetes mellitus, which is a pathology whose prevalence is nowadays in 
a remarkable increase, and insulin-resistance are linked to the development of 
heart failure, above all in the female sex, where the risk increases 5 times than 
in the healthy population.
22
 Furthermore diabetes correlates to a worse 
prognosis if heart failure occurs: the Olmsted cohort has shown that the 5-year 
14 
 
survival of patients suffering from both heart failure and diabetes was only 
37% compared to 46% of patients with heart failure but without diabetes.
23
  
 
Elevated cholesterol levels are a known risk factor for atherosclerotic vascular 
disease so they can be also correlated with heart failure. Although elevated 
concentrations of total cholesterol are not a strong predictor of the onset of 
heart failure, an increase in the ratio between total cholesterol and HDL are 
associated with a high risk of development of the pathology.
24
 
 
We must not forget the role of cigarette smoking: tobacco use remains the 
main avoidable cause of disease and premature death in the United States of 
America. The current smokers have a higher risk of developing heart failure 
compared to non-smokers and ex-smokers. The CASS (Coronary Artery 
Surgery Study) shows that smoking is independently associated with an 
increased risk of heart failure by 47%.
25 
 
1.4 Physiopathology of heart failure 
Heart failure can be seen as a progressive disease that is to realize from the 
moment when an index event leads to a damage of the heart muscle, with a 
consequent loss of function of cardiomyocytes or to a disruption of the ability 
of the myocardium to generate force with inability of the heart to contract 
normally. Regardless of the nature of the pathogenic cause, the common 
15 
 
feature of each of these index events is that all lead to a decrease in the 
pumping function of the heart.  
 
In response to the event that brings to an alteration of the systolic function of 
the left ventricle, some compensatory mechanisms trigger and precipitate, 
ultimately, in compensated (then mostly asymptomatic at the clinical level) 
heart failure at first and finally decompensated. 
 
1.4.1 The neurohormonal model 
The first compensatory mechanisms that the body puts in place are those 
included in the “neurohormonal model”, which comprises the activation of 
the sympathetic nervous system and the renin-angiotensin-aldosterone system. 
Numerous studies, carried out in the second half of the 90s, have shown that 
heart failure progresses because of an overexpression of biologically active 
molecules that determine a deleterious effect both on the heart itself and on 
the circulation.
26
 Actually it is emerged that a high proportion of classical 
neurohormones, primarily norepinephrine and angiotensin II, is not produced 
only at the level of the neuroendocrine system and so it acts in an endocrine 
way on the heart, but it is also synthesized within the myocardium itself, and 
then it acts in an autocrine and paracrine way.
27
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For what concerns the activation of the sympathetic nervous system, this is a 
phenomenon that develops early during the evolution of heart failure and it is 
associated with a parallel reduction of the parasympathetic tone. In standard 
conditions, inhibitory afferent fibres coming from the baroreceptors of the 
arch of aorta and from the carotid sinus as well as from the cardiopulmonary 
mechanoreceptors, are responsible of the inhibition of the sympathetic tone 
whereas the input coming from muscular metaboreceptors and from 
peripheral chemoreceptors, is the primary stimulus to sympathetic efflux; in 
patients with heart failure, instead, the inhibitory sign decreases to the 
detriment of the increase of excitatory tone and this causes a generalized 
growth of the sympathetic stimulation and in a weakening of the 
parasympathetic one (see Figure 1.2). This process determines a loss of the 
variability of the heart rate and an increase of the peripheral vascular 
resistances.
28
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Figure 1.2. Image illustrating the comparison between the normal balance between sympathetic and 
parasympathetic tone, and the alterations that occur in a patient suffering from heart failure.
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Consequently to the increase of the sympathetic tone, there is an increase of 
circulating levels of noradrenaline (NA) as a result of both its increased 
synthesis and reduced reabsorption from the nerve endings. In patients with 
heart failure in the early stages, we can find circulating norepinephrine at 2-3 
times higher levels than the normal values. With the progression of the 
disease, instead, there is a marked reduction in the levels of this 
neurohormone as a result of a phenomenon of “exhaustion” following the 
prolonged activation of the cardiac sympathetic nerves but also the reduced 
activity of myocardial tyrosine-hydroxylase, which is the speed-limiting 
18 
 
enzyme in the synthesis of noradrenaline. As a proof of this process, 
performing a myocardial scintigraphy using MIBG 
(Metaiodobenzylguanidine, normally taken up by adrenergic nerve terminals) 
marked with iodine-131, we can see that the uptake does not occur in a 
normal way, which indicates a compromised reabsorption of NA.
30
 
In the presence of high concentrations of norepinephrine, the stimulation of 
the sympathetic receptor β1 in myocardiocytes plays an inotropic and 
chronotropic positive effect with a consequent increase in cardiac stroke 
volume, while the stimulation of α1 vascular receptors causes peripheral 
vasoconstriction. This is a mechanism that tries to compensate the inability of 
the heart to perfuse the peripheral organs but actually increases the energy 
requirements of the myocardium itself and thus aggravates ischemia under 
conditions of already-reduced oxygen concentrations, which can even lead to 
sudden cardiac death.
31
 
 
Differently from the sympathetic nervous system, the components of the 
renin-angiotensin-aldosterone system are activated at a later time. It seems 
that the leading cause of the induction of this system lies in the renal 
hypoperfusion, which derives from the reduced cardiac output. 
The main hormone of the activation cascade is the angiotensin II (AG-II), 
which, at short term, plays a homeostatic role on circulation but at a long term 
has harmful effects, since it determines the development of interstitial fibrosis 
19 
 
not only at cardiac level but also at renal and many other organs ones; 
moreover it may cause a worsening of the neurohormonal activation due to an 
increased release of noradrenalin and to the stimulation of the adrenal cortex, 
causing the secretion of aldosterone. The latter one, as the AG-II, supports 
firstly the circulation by promoting sodium reabsorption in the kidney, but in 
time induces hypertrophy and fibrosis in the myocardium and blood vessels 
with reduced compliance and increased ventricular stiffness; in addition it 
determines baroreceptoral and endothelial dysfunction and reduces the 
reuptake of norepinephrine with further worsening of heart failure.
32
 
Not to be forgotten the fact that the activation of RAAS causes, in the last 
instance, marked hydrosaline retention, one of the most significant aspects 
from a clinical point of view of heart failure.  
 
In order to thwart the activity of these vasoconstrictors neurohormones, some 
mechanisms of counter-regulation trigger. 
In patients with heart failure we can record high levels of prostaglandin E2 
and prostacyclin I2, which act through a vasodilator mechanism and 
counteract the hydrosaline retention. 
The natriuretic peptides, including the atrial natriuretic peptide (ANP) and the 
brain natriuretic peptide (BNP), are secreted by heart chambers in relation to 
the transmural pressure, often consequent to the increased hydrosaline 
retention, largely contributing to the maintenance of the pressure-volume 
20 
 
homeostasis.
33
 In fact, they act at renal level by promoting the excretion of 
water and sodium and inhibiting the release of renin and aldosterone, on 
vessels with a vasodilating effect, as well as on many organs with an anti-
fibrotic effect. Therefore we can easily understand how, above all in the early 
phases of heart failure, their role is important to prevent a quick worsening of 
the condition due to vasoconstrictor neurohormones. In advanced heart 
failure, however, because of many still-obscure reasons, their action seems to 
be weakened, leaving plenty of time and space to the RAAS activity.
34
 
Nevertheless the close relationship between the plasmatic concentrations of 
these peptides and the cardiac load, led to their use as cardiac-health markers 
with diagnostic and prognostic applications in a variety of illnesses that affect 
the cardiovascular system; in particular the BNP and its N-terminal fragment 
(NT-pro-BNP) – that despite of its biological helplessness, it is secreted in a 
same molar quantity than the first one – have been valued for their use in the 
management of heart failure and, in part, in its diagnosis as well, even though 
their concentrations are influenced also by the age and the possible presence 
of renal comorbidity.
35
 
 
1.4.2 Cardiac hypertrophy and left ventricular remodeling 
At a long term, the maintenance of the neurohormonal imbalance in favour of 
vasoconstrictor hormones, as well as the pathogenic cause underlying the 
heart failure, leads to the development of cardiac hypertrophy. 
21 
 
A hypertrophy is an increase of cell size with a consequent increase of the 
organ size. This increase in volume is correlated to an increased synthesis of 
the structural components of a cell. The hypertrophy can be either physiologic 
or pathologic, and at the base there is an increased functional demand or a 
specific hormonal stimulus.
36
 
 
The cardiomyocyte is generally considered as a cell with terminal 
differentiation that has lost its ability to divide, thus an increase of the 
mechanical load of the heart does not cause an increase in the number of cells 
(hyperplasia), but just a hypertrophy. The number of blood vessels and their 
relationship with the number of the cells remain unchanged. 
The increase in the mechanical work caused by pressure or volume overload 
or by trophic signals increases the synthesis of proteins, the amount of 
proteins in each cell, the number of sarcomeres and mitochondria, the size and 
mass of myocytes, therefore lastly the size of the heart.
37 
 
Furthermore the kind of hypertrophy reflects the nature of the stimulus. We 
can classically distinguish two kinds of hypertrophy: 
 Eccentric hypertrophy: by this we mean the increase of the number of 
sarcomeres for serial affixing (see Figure 1.3 and 1.4). Fibres turn out 
to be longer and the ventricular chamber turns out to be bigger. This 
volume enhancement is obtained without fibre stretching, namely 
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without an increase of preload in sense of an increase of strain, scilicet 
as the detente of sarcomere. With this process, the heart can be even 
doubled in volume while the end-diastolic pressure is normal. This 
adaptation is impossible to have with the dilatation mechanism. The 
eccentric hypertrophy intervenes as a compensation in volume 
overloads, namely when the heart has to increase, a lot and chronically, 
the ventricular load without elevating the pressure and the heart rate.  
 Concentric hypertrophy: by this, instead, we mean the increase in the 
number of sarcomeres for parallel affixing (see figure 1.3 and 1.4). The 
fibre is therefore thicker and the volume of the ventricular chamber 
does not change while the wall is thickened. Thus the ventricular mass 
increases and so the mass/volume ratio. Sometimes the thickening takes 
place towards the interior of the chamber that will be then reduced in 
volume. The concentric hypertrophy always involves unfavourable 
consequences for the cardiac dynamics, for example: it increases the 
distance between the capillary vessels and the centre of the fibre, 
therefore it creates a certain cellular hypoxia in some areas which leads 
to a loss of contractility; it increases the fibrous component and thus 
increases the average stiffness of myocardial tissue, and consequently 
decreases the compliance of LV; bridges of connection between the 
fibres develop. In conclusion, in hypertrophy concentric, the fibre 
23 
 
distensibility decreases given that, to equal diastolic pressure, the force 
that stretches the fibre is lower (by the law of La Place). 
This kind of hypertrophy represents the compensation mechanism of 
chronic pressure overloads such as in aortic stenosis and in arterial 
hypertension. It is better to discern this form from the concentric 
remodeling, in which the mass/volume ratio has increased without a 
mass increasing (thus the volume is reduced).
38
 
 
        
          
Figure 1.3 The concentric and eccentric hypertrophy can be distinguished through the orientation with which 
the sarcomeres are added.
39
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Figure 1.4 Scheme of cardiac and cellular remodeling, that occurs in response of the hemodynamic overload 
depending on the nature of the provoking stimulus.
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1.4.2.1 The meaning of hypertrophy  
The force-velocity and pressure-output curves show an inverse relationship 
between the ability to develop force and the one to shorten. This inverse 
relationship has its foundation in biochemistry and thermodynamics of the 
contraction. From these considerations, derives that the maximum power 
(obtainable from the product of the pressure for the output or, in case of fibre, 
from the product of the force for the shortening velocity) can occur only at an 
average level of force or pressure. Practically the heart always tries to place 
itself into a certain condition in order to work at the highest power, and so the 
25 
 
compensation mechanisms tend to keep the contraction force – namely the 
diastolic and systolic stress – constant. 
When a chronic overload interferes, the compensation is given by the 
hypertrophy or by the concentric remodeling that work precisely, 
standardizing the systolic stress. From the law of La Place we know that 
h
pR
T
2
  (where T = parietal tension, p = pressure, R = radius, h = parietal 
thickness) thus to keep the stress constant, if p increases (systolic overload) 
the R/h ratio must decrease. This is obtained through the concentric 
hypertrophy, which models the heart in order to increase the thickness without 
changing, or even diminishing, the radius. If the radius enhances (volume 
overload), instead, the thickness must increase a bit, because the R/h ratio 
must be constant. 
 
The constancy of the R/h ratio or its equivalent’s one, perhaps more used, 
mass/volume is therefore necessary to ensure the optimization of the 
contraction force. If this contraction force is normal (diastolic stress), the 
hypertrophy is “adequate”. In the normal pressures field, the hypertrophy is 
appropriate when the mass/volume ratio is equal to 1 or when R/h < 4. The 
optimal mass/volume ratio is equal to 0.8% and if this value is in default, the 
hypertrophy is “inadequate”. This is a characteristic of failing hearts, at least 
potentially, because they act in suboptimal zone for an excess of afterload. 
26 
 
Eventually, if the hypertrophy is excessive and so the systolic stress is 
decreased, the hypertrophy is called “inappropriate”.38  
 
1.4.2.2 Structural alterations of the myocardial architecture 
Several studies have demonstrated how the cardiomyocytes hypertrophy 
causes some modifications of the myocyte biological phenotype that follow 
the reactivation of a group of genes that are normally not-expressed after 
birth. The reactivation of these foetal genes, the so-called foetal genetic 
program, is also accompanied by the reduced expression of genes normally 
expressed in the adult heart. The stimuli for the myocyte genetic 
reprogramming include the stretch-strain of the myocyte itself, 
neurohormones (such as NA, AGII), the inflammatory cytokines (such as the 
endothelin) and the reactive oxygen species, ROS, (for example superoxide, 
NO). These stimuli act locally inside the myocardium where they exert 
autocrine and paracrine effects, as well as at systemic level where they 
produce endocrine effects. 
 
The beginning phase of cardiomyocytes hypertrophy is morphologically 
characterised by increases in number of myofibrils and mitochondria, as well 
as by the enlargement of mitochondria and of nuclei: the cell overall looks 
bigger although with a subcellular organisation still preserved. As the 
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hypertrophy advances, instead, mitochondria increase in number and new 
contractile elements are added in some confined areas of the cell itself.      
When subjected to long-term hypertrophy, cells thus show a clear subversion 
of the cellular architecture such as markedly enlarged nuclei with greatly-
lobulated membranes, associated with displacement of adjacent myofibrils 
with loss of the normal recording of Z-bands. Eventually, the late stage of 
hypertrophy is characterized by the loss of the contractile elements 
(myocytolysis) with marked disruption of the Z-bands and severe subversion 
of the normal sarcomeres parallel arrangement, associated with dilation and 
increased tortuosity of the T-tubules (see Figure 1.5).
41 
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Figure 1.5 Histopathology of hypertrophy 
A. The beginning phase of cardiac hypertrophy is morphologically characterized by the increase in number 
of myofibrils and mitochondria and in volume of mitochondria and nuclei. Myocelles are larger than the 
normal ones but the cellular organization is mostly preserved. 
 
B. At a more advanced phase of hypertrophy, cells increase preferentially the volume or the number of little 
specific organs such as the mitochondria and we can observe the addition of new contractile elements in 
some cellular areas that lead to a cellular ultrastructure and borders abnormality; the surrounding cells can 
have variously increased in volume. 
 
C. Cells that are subjected to a long-term hypertrophy show obvious abnormalities of the molecular 
structures such as markedly enlarged nuclei with greatly-lobulated membranes, that cause displacement of 
adjacent myofibrils and so the alteration of  the normal recording of Z-bands. 
 
D. Eventually, the late stage of hypertrophy is characterized by the loss of the contractile elements, marked 
disruption of the normal sarcomeres parallel arrangement, fibrous tissue deposition and dilation and 
tortuosity of the T-tubules.
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One of the main problems of a heart that undergoes a hypertrophic 
programme is linked to the proliferation of the connective tissue component 
that accompanies the cardiomyocytes hypertrophy and, in a last instance, 
leads to the development of interstitial fibrosis. In fact, besides the increase of 
muscle mass, strictly speaking, cardiac hypertrophy also concerns the 
 
A. 
 
 
B. 
 
 
C. 
 
 
D. 
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proliferation of non-myocyte elements, in particular fibroblasts, and the 
deposition of the extracellular material.
43
 This aspect is found primarily in the 
ventricles with pathological hypertrophy, whereas in physiological 
hypertrophy is marginal and therefore we tend to think that this is exactly the 
crucial difference between the pathological hypertrophy and the athlete’s 
heart.
44
 
 
As demonstrated a long time ago, it is possible to observe cardiac fibrosis in 
many conditions, in presence of both volumetric and pressure overload; in 
these circumstances, we observe a thickening of the fibrillar collagen and a 
remodeling of extracellular matrix up to the disappearance of myocardial 
fibrosis, which, when is in excess, markedly contributes to the ventricular 
dysfunction. 
 
In the chronic pressure overload, the structural remodeling of the interstitial 
component of the LV wall does not regard, however, only the collagen 
accumulation. Particular importance is in fact covered by modifications that 
affect the collagen architecture. In animals suffering from pressure-overload 
hypertrophy, it was demonstrated a pathological alignment of collagen fibrils, 
the so-called cross-hatching.
45
 These alterations have been reported also in 
men, where collagen fibrils have been pinpointed and these had an increased 
thickness with marked cross-hatching. In patients with aortic stenosis, this 
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particular interstitial remodeling turns out to be associated to a decrease in the 
ejection fraction and an increase in diastolic rigidity.
46
 
Is seems that at the base of the whole process there is – again – the 
angiotensin II and aldosterone activity. 
 
When the increase in ventricular mass is not due only to the myocyte 
hypertrophy but also to the interstitial fibrosis, some alterations of the 
nutrition of the myocardial tissue, that depend on an organic and functional 
transformation in a pathological sense of the coronary circulation, may occur. 
In the end, the association between fibrosis, increase of the intercapillary 
distance and decrease of the capillary density may contribute to compromise 
coronary reserve in these subjects. 
             
Just about the vascular aspect of hypertrophy, it is known that in the 
hypertrophic heart, compared to the increase muscular mass, the number of 
capillaries decreases per unit area. Moreover, the increase in dimension of 
myocytes, to which follows a reduction of the cellular volume/surface ratio, 
determines an increase of oxygen diffusion distance from blood to myocytes. 
Thus the hearts is in a condition of altered mass/vascular supply ratio, to 
which the development of myocardial hypoperfusion may follow. In the 
peculiar hypertrophy of the athlete’s heart, instead, we cannot observe any 
trophic disorders of cardiomyocytes. 
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In addition to the structural component, also functional factors contribute to 
limit the coronary reserve. It seems that a reduced ability of self-regulation of 
the coronary circle may contribute to the limitation of the coronary reserve of 
hypertrophic heart.
47
 
 
Recently attention has been focused on the modification of the endothelial 
response to the variations of coronary flux and in particular on a reduced 
synthesis of releasing factors of endothelial origin, such as the NO, and the 
overproduction of vasoconstrictor substances, such as the endothelin-1, that 
may be the cause of an increase on vascular resistances. The increase of 
MVO2 seems to contribute to alter the demand/offer ratio to the myocardial 
cell, above all at a subendocardial level, where – during the cardiac cycle – 
higher tension apply.
48
                   
 
1.4.2.3 The relationship between myocardial hypertrophy and heart failure 
As already said, it is now established that cardiac hypertrophy, even though it 
arises as adaptive process, at a certain point it comes to acquire the 
characteristics of a pathological phenomenon that leads to biomolecular, 
biochemical and morphological alterations of myocardium. When the 
hypertrophy gets inadequate, a sequence of events starts happening, and, 
through the expansion and the progressive deterioration of ventricular 
function, it may lead to the development of heart failure.
49
 At the base of the 
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functional hypertrophic LV deterioration there are many causes such as an 
altered cellular energy balance, the loss of contractile elements due to necrosis 
or apoptosis, modifications of the extracellular matrix and a reduced 
myocardial function that follows the expression of typical genes of foetal 
heart. 
 
The role of myocardial hypertrophy in heart failure pathogenesis is possibly 
crucial; the presence of a hypertrophy in hearts with chronic dysfunctions is 
almost detectable in a constant way. Nowadays, however, any kind of 
mechanisms able to provide a convincing explanation of the process that leads 
from the hypertrophy to heart failure has been proved. In the context of a 
cardiac disease, hypertrophy can be seen as an intermediate stage between the 
initial myocardial damage and subsequent irreversible myocardial failure. 
Probably in the evolutionary history of hypertrophy, the overlap of alterations 
of the structural components of myocytes related to parietal stress, of 
myocardial nutrition and of intervention of biochemical factors related to the 
overload but also to the basic pathogenic cause, will lead to a shift from 
adaptive to pathological hypertrophy.  
 
In the 60s, Meerson and colleagues,
50
 relying on studies conducted on rabbits, 
defined the phases in which the evolution from hypertrophy to left ventricular 
failure consists. The first stage corresponds to the initial myocardial injury, 
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which can be derived from the underlying presence of an overload or it can be 
the primary cause of the overload of the remaining healthy myocardium itself; 
later a condition of stable hyperfunction establishes, followed by a stage of 
exhaustion and fibrosis. This sequence is observable in conditions of acute 
hemodynamic overload, in which a temporary and initial impairment of the 
ventricular function turns up, followed by an usually-prolonged period of 
return to normality and it finishes with an evolution into cardiac disease; in 
the majority of valvular illnesses and in arterial hypertension conditions, the 
first stage is hardly recognisable because the overload establishes gradually. 
On experimental laboratory preparations, it is possible to record how, in 
response to an acute overload, an asynchronous synthesis of contractile 
proteins occurs, as well as an abnormal genesis of subcellular structures, 
besides to an inadequate increase of the capillary network and a deposition of 
abnormal quantities of connective tissue. Moreover, in the isolated and 
working heart of rats subjected to the effects of acute pressure overload, it 
was observed a significant increase of the heart weight, reflecting the 
presence of myocardial oedema, associated to a quick and marked depression 
of the ventricular function. By analysing the ultrastructural data, it turned out 
a significant increase of the interstitial space, combined with signs of cellular 
necrosis, mitochondrial alterations and fragmented and disoriented myofibrils. 
Furthermore, the excess of interstitial fluid can determine an impairment of 
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the myocardial perfusion through the increase of the diffusion distance of 
oxygen and the extravascular compression of microcirculation. 
In the following phase of stable hyperfunction (stage II), the ventricular 
hypertrophy represents a compensatory phenomenon to the elevated load due 
to the high parietal stress. As already said, as long as the hypertrophy is able 
to balance the hemodynamic load, while maintaining the wall stress, it is 
called «adequate hypertrophy». At this stage, the myocardium is able to 
function normally, developing high isometric tensions and supporting an 
increased mechanical work for extended periods, even months or years. 
However, this incessant overload may lead to exhaustion of the capacity of 
myocytes to synthetize, to intracellular accumulation of calcium, to alteration 
of the balance of myocardial oxygen and to interstitial remodeling. At this 
stage, it can already be demonstrated the presence of reactive fibrosis and 
small areas of reparative fibrosis localized mainly in the subendocardial area; 
this is a prerequisite for the transition to structural changes that accompany 
the development of inadequate hypertrophy. Probably myocyte apoptosis may 
play an important role in the progression to myocardial failure, as well. 
Eventually, the next phase of exhaustion and progressive cardiosclerosis 
(stage III) denotes the final stage, in which the muscular cells presents 
degenerative phenomena, they can come across death and can be substituted 
by fibrotic tissue. The clinical manifestations of heart failure are the 
consequence of the progressive myocardial damage that occurs in the face of 
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a state of non-compensatory hypertrophy. From an ultrastructural point of 
view, we can see myocellular injuries that include: magnification and 
deformation of nuclei, disorganization of the structure of sarcomeres, 
proliferation of T tubules, accumulation of lipofuscins and glycogen. In more 
advanced stages, the most obvious change is the decrease of the myofilaments 
until the demise of sarcomeres which can cause cell death and later the 
progressive replacement by fibrous connective tissue. 
The prevalence of sclera-regressive processes seems to lead to phenomena of 
tissue remodeling, because of the increase of interstitial fibrous component 
and through the alteration of the relationship between myofibrils and 
connective microcirculation. An extensive subendocardial reparative fibrosis 
is now a known event and amply histologically demonstrated.       
 
It is important to underline how in compensatory hypertrophy (with a high 
mass/volume ratio), the evolution is generally favourable in a short term 
period; instead when there is a kind of non-compensatory form (with a low 
mass/volume ratio), the evolution of the disease is unfavourable from the 
beginning. An unfavourable mass/volume ratio in a hypertrophic ventricle 
helps to diminish the ability of heart to pump blood and so increases the 
parietal stress; these phenomena, in turn, affect the neuroendocrine activation 
and therefore the perpetuation and the aggravation of the vicious circle. 
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In patients suffering from idiopathic dilated cardiomyopathy of recent onset, 
it was observed that the ones that had an elevated mass/volume ratio survived 
better and had a minor number of hospitalizations during the follow-up. In 
patients with ventricular dilatation and a low mass/volume ratio, in which the 
parietal stress was permanently high despite of the presence of a ventricular 
hypertrophic response, instead, the evolution of the illness tended to be 
unfavourable because of the presence of an inadequate hypertrophy. 
Nonetheless, at a long term even the compensatory hypertrophy, which 
initially is a mechanism of adaptation to the overload, has the tendency to 
evolve towards the myocardial insufficiency. 
 
In front of a patient suffering from myocardial hypertrophy or from heart 
failure is thus important to evaluate the characteristics of the left ventricular 
chamber, above all the mass, the volume and the cardiac output, in order to 
define the entity of the reserve of the ventricle itself to pump blood compared 
to the potential energy stored in the ventricular mass. Determining the ability 
of the ventricle to develop work, both in basal conditions and under stress, is a 
key prognostic factor as well as the foundation of therapy which is then 
administered to the same patient.  
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2  THE HEART AS A PUMP 
 
The heart can be compared to a pressure generator, or a pump, put at the 
beginning of a system of conducts within which blood flows and where blood 
comes to, after having flowed the entire circulatory system.
51
 The heart, in 
fact, getting the contractile energy from the chemical energy coming from the 
scission of high-energy-of-hydrolysis phosphates, supplies potential energy 
(volume energy) to a volume of blood. The arterial pressure represents the 
mechanical manifestation of the cardiac contraction. 
 
The hydraulic pumps are operating machines that, converting the mechanical 
energy into hydraulic energy, determine the passage of liquid substances from 
a lower energetic level to a higher one; they transform the mechanical energy 
(usually provided by an electrical engine) into hydraulic energy, generally in 
the form of potential energy. 
 
In particular, we can compare the heart to a volumetric pump because it 
develops its action through the alternation of filling and emptying of a closed 
volume. In practice, volumetric pumps consist in a cylinder of a variable 
capacity, so that, when the pump is placed in communication with the 
container from which the liquid comes from, the volume increases, while the 
volume decreases when the pump is in communication with the container in 
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which the liquid flows. In the volumetric machines field, those who are 
alternative, are characterised by chambers in which the liquid remains stuck 
for a long or a short period of time, experiencing, it that period of time, an 
increase in energy; the cambers are sometimes set in communication, through 
valves, to the conduct, to which are linked, and, as a consequence, a back-
and-forth movement is created above the liquid by the moving surface.
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The functioning of the cardiac pump is similar to the suction-delivery pump 
(see Figure 2.1), whose description dates back to the I century B.C. by 
Vitruvius: by raising the piston of this pump, we form a depression in the 
inferior chamber that leads to the opening of the outlet valve; by lowing the 
piston, afterwards, the pressure in the cylinder increases and determines the 
opening of the discharge valve and the passage of the liquid in the upper 
chamber.
53
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Figure 2.1  Suction – delivery pump 52 
 
 
The ventricular pump is formed by muscular fibres in a circular and 
longitudinal arrangement and by a net of connective support: this particular 
conformation let the transfer of energy form the walls towards its content. The 
ventricular muscular fibres contraction, that has the task to generate potential 
energy, is spent partially to win the forces that oppose to the emptying and 
partially to move a volume of high-pressured blood equal to the systolic 
stroke volume. 
 
The ventricular chamber is comparable to a camber that sets in 
communication a low-pressured system with a high-pressured one. Recently, 
relying on a theory according to which the myocardium would be formed by a 
Piston 
Outlet 
valve 
Suction 
valve 
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single muscular band, bent to form some spirals that form the ventricular 
chambers, permitted to interpret the function of the ventricular pump 
comparing it to a pump formed by a cylinder in which a piston slides: the 
most external loop would represent the cylinder walls, the most internal one, 
instead, the piston.
54, 55, 56
 
 
Similarly we can consider the cardiac valves as the ones present in the 
mechanical pump because they open up when the pressure in the upstream 
chamber becomes higher than the downstream one, both for an increase in the 
upstream pressure (as for semilunar valves) and for a decrease in the 
downstream pressure (as for the atrio-ventricular valves). The closure instead 
happens when there is a pressure gradient that drives the blood back, with a 
greater speed the greater is the velocity of the blood stream. 
 
2.1 Cardiac work  
As it emerges from one of the basis of classical physics, the equality between 
work and energy, it turns out that the cardiac pump has to develop work to 
assure to blood the energy necessary to the circulation. The myocardial 
contraction energy is transferred to the blood contained in the ventricular 
chamber through a force exerted through the movement of the endocardial 
surface. The energy developed is then directed, thanks to the cytoskeleton 
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endosarcomerical proteins, before to the cardiomyocyte and then to the fibres 
and to myocardial walls. 
The left ventricle, at each beat, performs a work called pressure-volume 
systolic work or external work, evaluable through the formula: 
 
SVppW RaAo  )(  
 
In which pAo is the aortic medium pressure, pRa is the right-atrium medium 
pressure and SV is the stroke volume. If we consider the right-atrium pressure 
as negligible, the formula can be approximated to: 
 
W = arterial medium pressure SV  
 
The unit of measurement is the work one: 
JoulemNewtonm
m
Newton
mPascal  3
2
3 . 
 
As we can infer form the formula, the cardiac work process considers the 
attribution of an energy, under a pressure energy form, at each cardiac cycle, 
to a volume of blood that is pushed in the circulatory system, gaining over the 
forces that every time thwart.
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There are actually some limits to this valuation, mainly coming from the 
assumption of a constant pressure during the process of the systolic pressure. 
To evaluate better the expulsion work we must consider the ventricular 
pressure at each instant of the ejection phase (instead of the arterial medium 
pressure) and the volume variation at each moment of the ejection phase 
(instead of total variation). Therefore, given that the pressure and the volume 
change continuously during the cardiac cycle, the work done by the ventricle 
is more rightly expressed as the summation of the elementary works done at 
each instant of the contraction:  
 
                           ∫     
  
  
 
 
In this formula    is the systolic work,    e    are respectively the end-
diastolic and end-systolic volumes,    is the elementary volume and    the 
systolic ventricular pressure. 
 
We must then recall the existence of an acceleration work: the blood expelled 
from the ventricle has got a component of kinetic energy and one of potential 
energy that, respectively, leads it to accelerate and gain over the systemic 
vascular resentences.
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At each cardiac cycle the energy necessary to the development of the pump 
function does not regard only the external work, rather indeed this represents 
only a minor quota of the energy that is used, but the majority is utilized to 
put and keep in tension the myocardial fibres: we talk about internal work. 
This one cannot be quantified in mechanical terms but it has got a remarkable 
metabolic relevance because it partly depends on the myocardial consumption 
of oxygen.
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The chemical energy included in nutrients (glucides, lipids and proteins) and 
stored in high-energy phosphoric bonds, it is after mostly transformed in heat 
and it is dissipated by heart after having been used to the development of the 
internal work; eventually the remaining part is used to guarantee the blood 
sliding into the vessels.
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2.1.1 Pressure-Volume Diagrams 
To represent the totality of the energy generated by the ventricle during a 
cardiac cycle, we can use a pressure-volume diagram, like the one in Figure 
2.2: 
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Figure 2.2 Pressure-Volume diagram of the left ventricle during the cardiac cycle.
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A diagram like this shows the mutual relationships that subsist between 
ventricular pressures and volumes during the cardiac cycle, allowing to 
analyse the dynamic of the left ventricle and the filling and ventricular 
ejection ratios. The sequence, which must be observes anticlockwise, of the 
phases shown by the diagram begins in end-diastole, when in the left ventricle 
there is a low-pressure condition but the volume is elevated. The ascendant 
deflection follows, and this represents the isovolumetric contraction of the 
ventricular myocardium, in which an increase in the internal chamber-
pressure occurs, while the volume is unaltered (closed valves). We then 
observe a movement leftwards of the diagram in the ejection phase, in which, 
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with the opening of the semilunar valves, the emptying of the ventricular 
chamber begins, with a consequent decrease in volume while the pressure is 
unvaried. In the descendant portion of the diagram, that indicates the 
isovolumetric diastole, we realize how the pressure decreases, whereas the 
volume is constant: it is the isovolumetric diastole, which begins when the 
semilunar valves close and the ventricular fibres start stretching. In the end, to 
re-join to the starting point, we can detect a movement rightwards of the 
diagram: this corresponds the ventricular filling from the opening of the atrio-
ventricular valves, in which the internal chamber-volume enhances and this is 
accompanied by a slight pressure increase.  
 
In this same diagram, instead, the internal work can be depicted as the 
pressure-volume area inside the descendant part of the graphic (isovolumetric 
diastole) and the intercept on the work axis (see Figure 2.3).  
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Figure 2.3: Representation the external cardiac work and of the internal cardiac work in the pressure-
volume of the left ventricle during the cardiac cycle.
67
 
 
 
The summation of the external and internal cardiac work constitutes the total 
mechanical energy index of each heartbeat.
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There is a linear relationship between the total cardiac work and the 
myocardial consumption of oxygen.
62
 Given that the size of the pressure-
volume area of internal work increases with the volume, when we go and 
determine the functional characteristics of the left ventricle, it is essential to 
consider the position in which it operates along the axis of the volumes, above 
all in case of dilated and hypokinetic ventricles that, while developing a low-
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pressure-volume work, set a very high energy expenditure related to the 
amount of internal work in relation to the high ventricular size. 
 
The area under the diastolic portion of the pressure-volume curve represents 
the work done by the blood to fill the ventricular chamber, stored as elastic 
energy in the myocardial walls and then returned in the systolic phase. 
 
The pressure-volume diagrams are included between two curvilinear 
relationships between pressure and volume: the end-diastolic pressure-volume 
relationship (EDPVR) and end-systolic pressure-volume relationship 
(ESPVR).
63,64 
The first one is drawn through the junction between end-
diastolic points of each loop square (it is necessary to measure the pressure-
volume relationships under different load conditions) and has got curvilinear 
trend, derived from the passive non-linear properties of ventricular chamber; 
the second curve can be described, instead, by joining the end-systolic points 
and looks like a straight line. In each recording of a pressure-volume diagram, 
the end-systolic point falls on the ESPVR and end-diastolic point on the 
EDPVR curve. 
 
2.1.2 The ventricular elastance 
In order to evaluate the ventricular inotropic situation independently form the 
pre-load and post-load, we estimate the so-called ventricular elastance, which 
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is defined as the pressure variation that corresponds to a certain change of the 
ventricular chamber’s volume, calculable as the relationship between pressure 
and volume in end-systole in different load situations. It conveys some 
indications about the ventricular stiffness. It reaches the peak during end-
systole and it is a time-independent quantity. 
 
The formula obtained in the experimental environment to estimate the 
elastance is this one: 
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in which E(t) is the elastance (in mmHg) in time t from the beginning of the 
contraction, p(t) and V(t) are the instant pressures and the volume in the t 
instant respectively, while V0 is the ventricular volume – at pressure equal to 0 
– in systole. The slope of this straight line is identified with the maximum 
elastance value (Emax), which is the ratio between the end-diastolic pressure 
and the end-systolic volume (pED/VES); in clinical researches, anyway, the Emax 
value is usually approximated through the estimation of the end-diastolic 
elastance (EES), represented by the inclination of the ESPVR curve which is 
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usually a roughly straight line and not very sensitive to cardiac load-
dependent factors. 
 
In human beings, the elastance values can be determined by measuring 
repeatedly the ventricular pressures and volumes in end-systole in condition 
of changeable load: crescent values of post-load determine consensual 
increases of the pressure and volume in end-systole.  
 
If inotropism varies, the slope of the elastance straight line changes. In fact, 
after a positive inotropic stimulus (for example after catecholamine 
administration), the developed end-diastolic pressure and the systolic stroke 
volume increase, the end-diastolic volume decrease, the ejection work 
enhances and this is clear from the modification of pressure-volume loop. 
Consequently, the ventricular elastance straight line moves upwards and 
leftwards. On the other hand, a decrease of inotropism determines a reduction 
of the slope of the straight line (see Figure 2.4).
65, 66
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Figure 2.4: Change of the left ventricle pressure-volume diagram after the administration of 
catecholamine.
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2.2 Cardiac power 
After analysing the ability of heart to perform work, it is important to know 
the velocity in which this work is done, like in every mechanical system. The 
concept of work, in fact, leaves aside the one of time, so it can be done 
indifferently either in a long period of time or in a short one, although this 
may lead to different effects. Since the heart work is formulated, as we said 
before, in terms of pressures and volumes ( VpW Δ ), the cardiac power P 
can be calculated as: 
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so as the product of the pressure and the flux. During physical exercise, the 
ratio between the heart power and the weight of the organ is similar to those 
of mechanical pumps.
67
 
 
2.3 Myocardial efficiency 
Since the heat production represent the effect of energetic transformation that 
triggers form the liberation of chemical energy from the exergonic 
combustion of carbonic combustibles in presence of oxygen, we can express 
the cardiac pump efficiency as: 
                                        
In which      is the myocardial oxygen consumption. At a normal heart, it 
is attributed an average efficiency of 25%, but, since most of the energy that 
is consumed in the cardiac cycle is directed to the conduct of reactions that 
are independent of the contractile process, the efficiency of the contraction is 
undoubtedly higher than the one estimated. The efficiency of the ventricular 
contraction was quantified at around 30%, very similar to that of a 
mechanically propelled machine.
68, 69
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Recent studies 
70
 have provided a clearer picture about the mechanoenergetic 
effects of ventricular hypertrophy. In particular, it was shown that the 
myocardial oxygen consumption increases in response to the increased 
metabolic demand that follows the high workload being put on the ventricle 
that leaves unchanged but efficiency although it has been observed a non-
significant reduction. The work of ejection in hypertrophy does not change 
but the work developed per gram of tissue is disproportionately depressed in 
relation to changes in MVO2. Therefore the apparent normalization of oxygen 
consumption per unit of weight induced by the hypertrophy occurs at the 
expense of the mechanical efficiency. Actually, these alterations are not 
reproducible in presence of myocardial hypertrophy that follows an aortic 
stenosis
71, 72
 or arterial hypertension
73
 and this underlines the complexity of 
the various adaptive processes that occur with the hypertrophy that follows 
several pathogenic causes.
74
 Similarly, in the context of an appropriate 
hypertrophy, such as in the athlete’s heart, cardiac efficiency is normal. 
 
An altered myocardial efficiency represents, thus, an important prognostic 
factor in failing heart that lets us to evaluate how much, with the same mass 
increase, the myocardium is able to develop external work also compared 
with the oxygen consumption (fundamental aspect when the heart failure 
comes for a previous ischaemic heart disease).    
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2.4 Peak cardiac power output-to-left ventricular mass (peak CPOM) 
There is still room to improve prognostic stratification of high-risk outpatients 
with heart failure (HF). Prognostication of HF patients is based on readily 
available information that includes symptom severity (usually NYHA 
functional classification), left ventricular (LV) ejection fraction and 
natriuretic peptides. However, none of these parameters provide nuances of 
cardiac pump and circulatory system performance. Exercise stress 
echocardiography may endow with additional insights for prognostication of 
these patients.
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Cardiac power output (CPO), which is the product of mean arterial pressure 
(MAP) and cardiac output (CO), is a measure of cardiac energy delivery.
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This parameter has shown a great ability to predict outcome in a broad 
spectrum of cardiac disease both at rest
77, 78, 79, 80
 and during exercise.
81, 82
 
Echo-derived peak CPOM is a variable that couples peak CPO with LV mass 
at peak exercise or during maximal inotropic stimulation. Since it is a 
measure of the rate at which cardiac work is delivered with respect to the 
potential energy stored in LV mass, it provides information about the rate at 
which potential energy is transformed into useful work.  
Power-to-weight ratio is a measure that is widely applied to mechanical 
engines to compare the performance of vehicles, aircrafts and other mobile 
power sources. This ratio represents a measure of actual performance of any 
energy source or any engine. It is also used as the index of performance of a 
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vehicle as a whole by the ratio between engine power and its weight (less 
frequently its mass) to give rise to a parameter that is independent from the 
size of the vehicle. 
Every pump has its own maximum performance, which denotes its pumping 
capacity. Cardiac pumping capacity can be defined as the cardiac power 
output achieved by the heart during maximal stimulation. It represents the 
recruitable reserve available that is expected to be proportional to the number 
of contractile units of the myocardium. Similarly to any mechanical engine, 
an index that relate peak LV power output and LV mass, such as peak CPOM, 
may be considered as measures of LV pumping capacity. Indeed, it allows us 
to evaluate the relationship between recruited myocardial muscle mass and 
the power of the left ventricle at maximum workload. 
In view of the fact that normal heart muscle grows to match the workload 
imposed on it, the mass of the ventricular wall depends on the chronic load 
with which it is confronted.
83
 Therefore, a stronger ventricle with a greater 
muscular mass will contract to a higher LV power output under stimulation. 
Since cardiac power output is the product of cardiac output (CO) and blood 
pressure (BP), the myocardium grows when either its CO or its BP is 
augmented. The physiological example of the former is the increase in LV 
mass in athletes. When the integrity of myocardial structure is compromised 
owing to myocyte loss, interstitial fibrosis and scarring, a disproportion 
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becomes apparent between maximal peak CPO and LV mass and this leads a 
decrease of peak CPOM.
84
  
Recently, peak CPOM has proved to be an independent predictor of outcome 
in patients with advanced HF.
85
 
Cardiopulmonary exercise testing (CPET) is a valuable and accurate tool for 
risk stratification of HF patients, among several CPET variables peak VO2,
86
 
VE/VCO2 relationship and their combination have been identified as 
predictors of prognosis,
87,88
 and they are used for timing of heart 
transplantation and ventricular assist device implantation. However, gas 
exchange measurements are only indirect measures of cardiac function and 
sometimes cannot properly reflect the status of cardiac pump and circulatory 
system performance. It is interesting to know whether the assessment of peak 
CPOM during exercise testing may be comparable to CPET parameters to risk 
stratify HF patients. Hence, the present study was designed to compare the 
value of peak CPOM and CPET in the prognostic stratification of patients 
with chronic HF.  
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3  AIM OF THE STUDY 
 
Prognostication of HF patients is based on readily available information that 
includes symptom severity (usually NYHA functional classification), left 
ventricular (LV) ejection fraction and natriuretic peptides. However, none of 
these parameters provide nuances of cardiac pump and circulatory system 
performance. Exercise stress echocardiography may endow with additional 
insights for prognostication of these patients. 
The present study was designed to compare the value of peak CPOM, a 
variable that couples the peak CPO with LV mass at peak exercise or during 
maximal inotropic stimulation with cardiopulmonary exercise testing (CPET) 
variables in the prognostic stratification of patients with heart failure with 
reduced ejection fraction (HFrEF) due to LV dysfunction. 
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4  MATERIAL AND METHODS 
 
4.1 Population of the study 
This study included a total of 115 subjects (91 men and 24 women) with heart 
failure with reduced ejection fraction (HFrEF) [LV ejection fraction (EF) 
≤40%] and clinically stable enrolled at the Cardiovascular Diseases Unit 1, 
Cardiothoracic department, Cisanello Hospital, Pisa.  
 
4.1.1 Exclusion criteria 
The exclusion criteria were heart failure secondary to valvular heart disease, 
presence of aortic regurgitation, peripheral artery disease limiting the 
capability of performing exercise stress test and reduced exercise tolerance 
attributable to myocardial ischemia. The 115 study patients with HFrEF were 
under oral treatment with angiotensin converting-enzyme inhibitors or 
angiotensin II receptor blockers (95%), loop diuretics (78%), and beta 
blockers (72%), anti-aldosterone drugs (58%) and digoxin (21%). Beta 
blockers were withheld at least 48 hours before the test.  
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4.2 Echocardiography  
All patients underwent an ultrasound examination at baseline and during 
bicycle semi-supine exercise using an Acuson Sequoia C256 ultrasound 
instrument (Siemens, Mountain View, California) equipped with a 3.5-MHz 
transducer and harmonic imaging. 
Prior to exercise, a complete echocardiographic and Doppler examination was 
performed with the subject in left lateral supine position. The standard 
parasternal long-axis view as well as the three standard apical four-chamber, 
two-chamber and long-axis views were acquired optimizing gain setting, 
sector angle and depth. LV end-diastolic and end-systolic volumes were 
calculated according to the biplane Simpson’s rule. The LV mass index was 
determined by using the M-mode method according to the recommendations 
of the American Society of Echocardiography
89
. The LV outflow tract 
anteroposterior diameter was measured in the parasternal long-axis view and 
the LV outflow tract area was calculated as πr2 (cm2). The LV stroke distance 
(cm) was measured tracing the outer edge of the most dense (or brightest) 
portion of the spectral aortic tracing recorded from the apical 5-chamber view, 
with the PW Doppler sample volume positioned about 5 mm proximal to the 
aortic valve.
90
 Doppler tissue imaging longitudinal velocities were recorded 
with the sample volume placed at the junction between the septal and lateral 
LV wall and the mitral annulus in the 4-chamber view and peak early 
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myocardial wave (e’) velocities were measured. The ratio of mitral E peak 
velocity and averaged e’ velocity (E/e’) was calculated.91 Patients with more 
than mild mitral regurgitation were selected according to the vena contracta 
method.
92
 
 
4.3 Exercise echocardiography 
Symptom-limited graded bicycle semi-supine exercise was performed at an 
initial workload of 20 watts lasting for one minute; thereafter the workload 
was increased stepwise by 10 watts every minute. A 12-lead 
electrocardiogram and blood pressure determination were performed at 
baseline and every minute thereafter. 
At baseline and during each exercise level, Doppler-derived cardiac output at 
LV outflow tract, heart rate and arterial systolic blood pressure (BP) and 
diastolic BP (by cuff sphygmomanometer) were measured. Mean BP was 
estimated as follows: diastolic BP + 1/3 (systolic BP – diastolic BP). Stroke 
volume was calculated as stroke distance x LV outflow tract area and cardiac 
output as stroke volume x heart rate. Great care was taken to assure patient 
hold breathing at each acquisition time and to acquire three consecutive 
Doppler tracings. All measures were averaged over three consecutive cycles. 
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Peak CPOM was calculated as the product of a constant (K=2.22 x 10
-1
) with 
cardiac output (CO) and the mean arterial pressure (MAP) divided by LV 
mass (M) to convert the units to watts/100 g: CPO = K  CO (l/min)  MAP 
(mmHg)  M-1(g). 
 
4.4 Cardiopulmonary exercise testing (CPET) 
Incremental CPET was conducted on an electrically braked cycle ergometer 
(Ergoline, Milano, Italy), recording standard measurements (VO2, VCO2, 
VE/VCO2, heart rate and ECG, oxygen saturation, O2 pulse, peak VO2, 
breath frequency, Bf, and pulmonary ventilation, VE, by ZAN Ferraris 
CardioRespiratory software) according to ATS/ERS guidelines.
93
 All subjects 
performed CPET wearing a mask containing a pneumotachograph, connected 
to the software.  
Cardiac and breathing reserves were calculated during incremental CPET as 
following: a) maximum predicted values (220 - years of age) - maximum 
heart rate achieved during CPET; b) (FEV1 pre-test x 40) - VE max achieved 
during CPET.
94
 
Constant load CPET was performed at 80% of the maximal workload 
achieved during the incremental CPET. Before each constant load CPET, a 
forced flow-volume loop was recorded (pretest FEV1) and a rest Inspiratory 
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Capacity (IC) was measured; afterward, at 1 min intervals during each test 
and at 2 min intervals after the end of exercise, IC manoeuvres were still 
collected, in order to assess for the presence of dynamic hyperinflation. As 
maximum value of VO2 reached at the end of constant load CPET, we chose 
the mean value of VO2 measured over the last 30 s of loaded exercise.
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Exercise echocardiography and cardiopulmonary exercise testing were 
performed within 7 days according to standard symptom-limited exercise 
protocols. 
 
4.5 End Points of Event-Free Survival 
For event-free survival analyses, observation began on the date of index 
exercise stress echocardiography. End points were all-cause mortality and 
cardiac events (cardiac mortality or hospitalization for worsening heart 
failure). Event-free survival data were obtained through follow-up of patients 
and verified through local authority registry and hospital records. 
 
4.6 Statistical Analysis 
Data are presented as mean ±SD for continuous variables and as percentages 
for categorical variables. Continuous variables were compared using paired-
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samples and independent-samples Student’s t test. Categorical variables were 
compared by means of the χ2 test. 
Time-independent associations between variables and outcomes were 
assessed using receiver operating characteristic (ROC) curve analysis and 
logistic regression. Statistical comparison of ROC curves was performed 
using the method of paired ROC curves of Hanley and McNeil. Cox 
proportional-hazard regression analysis was used to identify predictors of 
outcome in time-dependent analysis. Kaplan-Meier curves were constructed 
and log-rank tests were used to test for differences between event-free 
survival curves. The likelihood ratio test was used to compare different 
multivariate Cox models by taking into account the different number of 
variables used in each model and to explore the incremental prognostic value 
of power/mass ratio over established clinical and echocardiographic 
prognostic variables. The log likelihood and the overall model χ2 (i.e., that 
calculated by testing the hypothesis that all regression coefficients for the 
variables in the model are identically zero) were calculated for each model. 
The probability level was p < 0.05 for all data examined.  
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5  RESULTS 
 
5.1 Characteristics of the study patients 
The study population comprised patients with heart failure that were in New 
York Heart Association (NYHA) class I or II (n=85) and NYHA class III or 
IV (n=30).  
They were followed-up for a mean period of 24±22 months. Sixteen patients 
(14%) died due to various causes and twenty-one patients (18%) were 
hospitalized for worsening heart failure. During the follow up, implantable 
cardioverter defibrillators (ICD) were implanted in 17 patients (15%) and 
cardiac resynchronization therapy (CRT) systems in 4 patients (3.5%).  
Patients’ characteristics are summarized in Table 5.1. 
Mean LV EF at peak exercise was 28±6% in patients with events and 32±6% 
in subjects with no events (p-value=0.0021). Instead, mean cardiac output was 
7.5±3.3 L/min in the group of patients with events and 9.7±2.8 L/min in the 
other group (p=0.0003). Peak CPO was between 0.9 and 2.7 W in 
hospitalized and/or dead patients and between 1.5 and 3.7 W in patients with 
no events, with a p-value of 0.0003.  Peak CPOM was found to be 0.58±0.25 
W/100 g in patients with events while 0.94±0.24 W/100 g in the others, with a 
p-value <0.0001.   
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From cardiopulmonary test, resulted that peakVO2 was 15±4 in patients with 
events and 18±5 ml/(mg*min) in the control subjects, respectively 57±18 and 
70±18% of predicted with a p-value of 0.0007. O2 pulse was 11±4 in patients 
with events and 12±4 100 ml/(beat*kg) in patients with no events. Finally, 
peak VE/VCO2 resulted 38±6 in the first group and 32±6 L/L in the second 
group of subjects with a p-value <0.0001.  
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Table 5.1: Characteristics of the study patients. Group 1 includes patients with combined event 
hospitalization for HF + all-cause death; group 2 comprises patients with no events.  
 
Variable Group 1 
(n=37) 
Group 2  
(n=78) 
p-value 
Age (years) 61±12 62±11 ns 
Male gender (%) 81 79 ns 
NYHA class III-IV (%) 49 24 0.0092 
BMI (kg/m
2
) 28±5 27±4 ns 
CRT (%) 41 15 0.0029 
ICD (%) 62 19 <0.0001 
PeakVO2 (ml/(kg*min)) 15±4 18±5 0.0007 
VO2 predicted (%) 57±18 70±18 0.0004 
O2pulse (100 ml/(beat*kg) 11±4 12±4 0.027 
peak VE/VCO2 (L/L) 38±6 32±6 <0.0001 
Circulatory power 1941±964 2853±1377 0.0004 
LV EF (%) 28±6 32±6 0.0021 
LV E/e' ratio 15±9 11±5 0.0013 
Peak CO (L/min) 7.5±3.3 9.7±2.8 0.0003 
Peak CPO (W) 1.8±0.9 2.6±1.1 0.0003 
Peak CPOM (W/100 g) 0.58±0.25 0.94±0.34 <0.0001 
Digoxin (%) 32 16 0.042 
ß-blockers (%) 67 78 ns 
Diuretics (%) 97 71 0.0011 
ACE-inhibitors (%) 91 93 ns 
Anti-aldosterone drugs (%) 78 50 0.0031 
 
Data are expressed as mean ± SD or as percentages. 
Legend: BMI = Body mass index; CRT = Cardiac resynchronization therapy; EF = ejection 
fraction; ICD = Implantable cardioverter defibrillator; LV = left ventricular; peak CO = peak 
Cardiac output; peak CPO = peak Cardiac power output; peak CPOM = peak Cardiac power 
output-to-left ventricular mass. 
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5.2 Time-independent analyses of event-free survival 
Results of ROC analysis for outcome prediction are shown in Table 5.2 and 
5.3. For compound “death+hospitalization” events, among all variables, peak 
CPOM showed the largest area under the curve (AUC=0,816). A value of 
≤0.60 watt/100 g was identified as the best cut-off value, showing 70% of 
sensitivity and 85% of specificity for the prediction of events. After peak 
CPOM, peak VE/VCO2 has the second largest area under the curve 
(AUC=0,757); a value of >32 L/L was found to be the best cut-off, with a 
sensitivity of 80% and a specificity of 60%. Similarly, for death events only, 
CPOM showed the largest area under the curve (AUC=0,795); the best cut-off 
resulted to be ≤0.60 watt/100 g in the same way, showing 75% of sensitivity 
and 77% of specificity.  
 
Figure 5.1 displays the comparison of ROC curves of peak CPOM and LV 
ejection fraction for compound events and death events. Statistically 
significant differences between the areas under the curve were apparent in 
both cases between peak CPOM with respect to LV ejection fraction.  
 
Results of univariate and multivariate logistic regression are shown in Table 
5.4. Although a number of variables were associated with the risk of events, 
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stepwise multivariate analysis showed that the only independent predictor was 
peak CPOM (overall model p<0.0001). 
 
Table 5.2 ROC curve analysis for death +hospitalization events 
Variable Area 
under the 
curve 
95% CI p-value 
NYHA class III-IV 0,676 0,582 to 0,760 0,0004 
EF 0,692 0,599 to 0,775 0.0002 
Peak CO 0,737 0,647 to 0,815 <0.0001 
Peak CPO 0,751 0,661 to 0,827 <0.0001 
Peak CPOM 0,816 0,733 to 0,882 <0.0001 
PeakVO2  0,691 0,598 to 0,774 0.0003 
VO2 predicted 0,718 0,626 to 0,798 <0.0001 
Peak VE/VCO2 0,757 0,677 to 0,832 <0.0001 
 
Legend: EF = ejection fraction; peak CO = peak Cardiac output; peak CPO = peak Cardiac power output; 
peak CPOM = peak Cardiac power output-to-left ventricular mass. 
 
Table 5.3 ROC curve analysis for death events 
Variable Area under 
the curve 
95% CI p-value 
NYHA class III-IV 0,598 0,503 to 0,689 0,1651 
EF 0,735 0,644 to 0,813 <0.0001 
Peak CO 0,698 0,605 to 0,780 0.0181 
Peak CPO 0,704 0,611 to 0,785 0.0156 
Peak CPOM 0,795 0,710 to 0,865 <0.0001 
PeakVO2  0,720 0,629 to 0,800 0.0026 
VO2 predicted 0,714 0,622 to 0,794 0.0094 
peak VE/VCO2 0,723 0,631 to 0,803 0.0001 
 
Legend: EF = ejection fraction; peak CO = peak Cardiac output; peak CPO = peak Cardiac power output; 
peak CPOM = peak Cardiac power output-to-left ventricular mass. 
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Figure 5.1 ROC curves comparing peak LV ejection fraction and peak CPOM for the prediction of adverse 
events “death + hospitalization” (above) and “death” events (below) at follow-up.  
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Table 5.4 Univariate and Multivariate logistic regression 
Variable Univariate Multivariate 
Wald P-value OR P-value 
EF 8.20 0.0042   
Peak CO 11.91 0.0006   
Peak CPO 15.35 <0.0001   
Peak CPOM 24.85 <0.0001 13.51 <0.0001 
peakVO2 9.98 0.0016   
VO2 predicted 10.13 0.0013   
 
Legend: EF = ejection fraction; peak CO = peak Cardiac output; peak CPO = peak Cardiac power output; 
peak CPOM = peak Cardiac power output-to-left ventricular mass. 
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5.3 Time-dependent analyses of event-free survival 
In time-dependent analyses, when the patients were divided using the cut-off 
value of LV ejection fraction (EF) of 30% identified by ROC analysis, 
differences in the event-free survival probability were observed (p=0.0005, 
Logrank: 12), as shown in figure 5.2. Subjects with an EF >30% had an 
event-free survival at 24 months of 80%, and those with an EF ≤30% of 
≈50%.  
Considering the peak CPO instead, when the patients were divided using the 
cut-off value of 1.90 Watt identified by ROC analysis, significant differences 
in the event-free survival probability were observed (p<0.0001, Logrank: 
24.5), as shown in figure 5.2. Subjects with a peak CPO >1.90 watt had an 
event-free survival at 24 months of 82%, and those with a peak CPO ≤1.90 
watt of ≈40%. 
In addition, when the patients were divided in two groups using the cut-off 
value of peak CPOM of 0.60 watt/100 g identified by ROC analysis, 
significant differences in the event-free survival probability were observed 
(p<0.0001, Logrank: 34.1), as we can see in figure 5.2. Subjects with a peak 
CPOM >0.60 watt/100 g had an event-free survival at 24 months of 8%, and 
those with a peak CPOM ≤0.60 watt/100 g of 29%. 
With regard to the parameters of the cardiopulmonary exercise testing, in 
time-dependent analyses we can observe differences in the event-free survival 
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probability dividing patients into two groups with peakVO2 cut-off value of 
14 ml/kg/min (p=0.0037, Logrank: 4.8) identified by ROC analysis (figure 
5.2). Subjects with a peakVO2 >14 ml/kg/min had an event-free survival at 
24 months of 77% and those with a peakVO2 ≤14 ml/kg/min, a free-event 
survival of ≈45%. 
 
If we consider only all-cause death events, in time-dependent analyses, when 
the patients were divided using the cut-off value of LV EF of 30% identified 
by ROC analysis, significant differences in the survival probability were 
observed (p=0.0009, Logrank: 10.9), as shown in figure 5.3. Subjects with a 
EF >30% had a survival probability at 24 months of 90%, and those with a EF 
≤30% of ≈70%. Instead, considering the peak CPO, if we divide subjects 
using 1.90 watt as cut-off value, identified by ROC analysis, differences in 
the survival probability were observed (p=0.0021, Logrank: 9.4), as shown 
in figure 5.3. Subjects with a peak CPO >1.90 watt had a survival probability 
at 24 months of 88%, and those with a CPO ≤1.90 watt of ≈65%. Regarding 
peak CPOM, when the patients were divided using the cut-off value of peak 
CPOM of 0.60 watt/100 g identified by ROC analysis, significant differences 
in the survival probability were observed (p<0.0001, Logrank: 19.8), as we 
can see in figure 5.3. Subjects with a peak CPOM >0.60 watt/100 g had a 
survival probability at 24 months of 91%, and those with a peak CPOM ≤0.60 
watt/100 g of ≈55%. Finally, in time-dependent analyses, dividing subjects 
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using the cut-off value of peakVO2 of 14 ml/kg/min identified by ROC 
analysis, significant differences in the survival probability were observed 
(p=0.0058, Logrank: 7.6), as shown in figure 5.3. Subjects with a peakVO2 
>14 ml/kg/min had a survival probability at 24 months of ≈90%, and those 
with a peakVO2 ≤14 ml/min/kg of 63%. 
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Figure 5.2 Comparison between Kaplan-Meier event-free survival curves for EF, peak VO2, peak CPO, peak 
CPOM 
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Figure 5.3 Comparison between Kaplan-Meier survival curves for EF, peak VO2, peak CPO, peak CPOM 
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6  DISCUSSION 
 
In our findings, it can be demonstrated, in line with previous studies, how 
peak CPOM is an extremely useful parameter in prognostic stratification of 
patients with HF with reduced ejection fraction. By subjecting patients to 
exercise echocardiography, we calculated peak CPOM as the product of a 
constant (K=2.22  10-1) with cardiac output (CO) and the mean arterial 
pressure (MAP) divided by LV mass (M) to convert the units to watts/100 g: 
CPO = K   CO (l/min)   MAP (mmHg)   M-1(g).  
Prognostication of HF patients is based on readily available information that 
include symptom severity (usually NYHA functional classification), left 
ventricular (LV) ejection fraction and natriuretic peptides. However, none of 
these parameters provide nuances of cardiac pump and circulatory system 
performance. Exercise stress echocardiography may endow with additional 
insights for prognostication of these patients.
75  
Beginning in the mid-1990s, consensus guidelines recommended the 
application of the CPET to supplement other clinical data in the management 
of patients with HF.
87
 In fact the CPET allows, by subjecting the patients to 
an effort, to assess the response of cardiorespiratory system to exercise and 
therefore stratify the prognosis according to the degree of compromise 
emerged.  
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Most investigators have found that peakVO2 (calculated as the ratio of 
cardiac output and arteriovenous oxygen difference) is the best CPET 
indicator of prognosis in patients with heart failure. This well-established 
variable can be thought of as integrating a number of factors which determine 
the severity of heart failure and the degree of functional limitation including 
cardiac reserve, skeletal muscle function, pulmonary abnormalities, and 
endothelial dysfunction.
86
 PeakVO2 correlates poorly with haemodynamic 
factors measured at rest which is consistent with the fact that these resting 
parameters do not reflect functional reserve. There is, however, a good 
correlation between maximum cardiac output and peakVO2.
96
 The 
measurement of peak VO2 was first described by Webber and colleagues as a 
method for characterising cardiac reserve and functional status in heart 
failure.
97
 Subsequently peakVO2 has been shown by a number of 
investigators to be of prognostic significance, with lower peak VO2 
predicting mortality and the need for cardiac transplantation (peak VO2 is 
currently one of the most important criteria to select patients for a heart 
transplant but also for a LVAD implantation). Attempts have been made to 
use percentage of predicted peakVO2 to improve the prognostic power of this 
measure. Percentage of predicted peak VO2 may account for factors such as 
age, sex, and muscle mass which may have a significant impact on 
peakVO2.
88
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In our study, statistical analysis confirmed the important role of 
cardiopulmonary exercise testing peakVO2 in the prognostic stratification of 
patients with advanced HF. Subjects with a peakVO2 <14 ml/kg/min had a 
particularly impaired prognosis. 
It is well know that exercise intolerance is one of the main manifestations of 
HF, varying directly with the severity of the disease. However, it is important 
to highlight how maximal oxygen consumption during cardiopulmonary 
testing depends not only on cardiovascular factors: many other pathological 
conditions (obesity, respiratory diseases, muscular diseases etc.)
98,99
 as well as 
cardiovascular deconditioning (poor fitness)
100 
can likewise lead to values in 
the CPET parameters, especially in peakVO2, which overlap with those of 
patients with heart failure; in addiction it does not consider the influence of 
LV remodeling and provides only an indirect assessment of left ventricular 
exercise function.  
Therefore, peakVO2 cannot prescind from exercise echocardiographic 
parameters to give a complete and correct assessment of the ability of the left 
ventricle to perform its function of pump.  
Peak cardiac power output (peak CPO), which is the product of mean arterial 
pressure (MAP) and cardiac output (CO) at the peak of the exercise, is a 
measure of cardiac energy delivery, reflecting the power developed from the 
left ventricle.
76
 Roul and colleagues
101
 were the first group to evaluate the 
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prognostic value of peak CPO during maximal exercise testing. In many 
following studies, this parameter has shown a great ability to predict outcome 
in a broad spectrum of cardiac disease both at rest 
102, 78, 79, 80
 and during 
exercise.
103, 81
  
The echo-derived parameter peak CPOM (which reflects the number of watts 
that are developed by 100 g of LV mass) allows us to evaluate the relationship 
between recruited myocardial muscle mass and the power of the left ventricle 
at maximum workload. It can give information about the rate at which 
potential energy stored in left ventricular mass is transformed into useful 
work. This parameter in fact, by coupling peak exercise LV power output, 
which incorporate BP and flow response of the cardiovascular system to 
exercise, and LV mass is an integrated measure of LV pumping capability.  
Dini and colleagues 
85
 recently proved that peak CPOM is an independent 
predictor of outcome in patients with advanced HF. The concept behind this 
index is that a stronger ventricle with greater muscular mass will contract to 
higher LV power output under stimulation. An increase in LV size is 
fundamental to the ability to generate a large stroke volume.
104
 Although 
abnormal pump function plays a major role in determining both 
pathophysiology and prognosis in patients with heart failure, also changes 
over time in LV size and structure are important in disease progression and 
outcomes.
89 
Transition to failure is accompanied by progressive LV cavity 
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enlargement and decline in the mass/volume ratio despite an increase in LV 
mass. We also know that left ventricular enlargement can help maintaining 
stroke volume despite reduced contractile function, and this has been 
considered a compensatory response.
86
 Therefore, in patients with heart 
failure, beyond the classic parameters used, as the ejection fraction, it is 
important to establish to what degree LV remodeling may be considered 
compensatory or maladaptive and this can simply be implemented using 
echocardiography at rest and during exercise.  In the evolution of cardiac 
remodeling we can observe how when the recruitable power output per unit of 
left ventricular mass reduces because of progressively decreasing ability of 
the myocardium to generate force to overcome the load, left ventricular 
function rapidly deteriorates.
91
 We must also consider that, in the process of 
cardiac remodeling, besides changes in the architecture of ventricular 
myocytes, there is a proliferation of the connective tissue component that 
accompanies the cardiomyocytes hypertrophy and, in a last instance, leads to 
the development of interstitial fibrosis. Finally when the increase in 
ventricular mass is not due only to the myocyte hypertrophy but also to the 
interstitial fibrosis, some alterations of the nutrition of the myocardial tissue, 
that depend on an organic and functional transformation in a pathological 
sense of the coronary circulation, may occur. 
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For this reason, it has been hypothesized that the combination of severely 
reduced LV performance at maximum workload and increased LV mass 
reflects an adverse ventricular remodeling process that might have an impact 
on the risk stratification of patients with heart failure with reduced ejection 
fraction. A reduced peak CPOM is likely to reflect all LV morphological 
changes we have analysed.  
LV ejection fraction is the most frequently used index of cardiac function, but 
it may not accurately reflect myocardial contractility, and it provides little 
prognostic information in patients with advanced heart failure. The 
interpretation of an ejection fraction <35% in a patient in NYHA class I with 
mild LV dilation may be quite different from that of an individual with class 
III symptoms associated with a severely dilated left ventricle.
105 
Both ejection 
fraction decreases reflect LV chamber remodeling despite relative preserved 
stroke volume. However, in one instance, compensatory LV remodeling 
dominates this decline, with a near normal residual myocardium capable of 
providing adequate cardiac reserve. In the other case, the entire LV 
myocardium is depressed, with little reserve pumping capacity. These two 
situations may look similar when assessed by conventional measures, such as 
LV ejection fraction or wall motion score index, but are very different by 
alternative approaches, such as cardiopulmonary testing or hemodynamically 
derived cardiac power output. 
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In order to ensure a correct and complete prognostic stratification of patients 
with heart failure with reduced ejection fraction, which takes account of all 
aspects which we have discussed, the best option is to submit the subjects 
both to exercise echocardiography and cardiopulmonary test so as to combine 
their results and get a full metabolic and cardiorespiratory profile of the 
patients.  
This study demonstrates how the parameter peak CPOM can represent an 
surplus value in the stratification of patients with heart failure with reduced 
ejection fraction, in addition to the criteria that are classically used in these 
patients, as the ejection fraction or the NYHA class. Furthermore, when peak 
CPOM is combined with CPET parameters, the prognostic stratification of the 
patients results more accurate and complete. 
 
6.1 Limitations 
Certain limitations to this analysis need to be mentioned. First, we did not 
include several articles potentially duplicating data, which may in turn have 
caused other information to be unintentionally excluded, although most 
clearly contained redundant information. 
Although three-dimensional imaging is the most accurate way to measure LV 
mass by echocardiography,
106
 M-mode methods are in current use in clinical 
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practice and suggested by the American Society of Echocardiography.
1
 
Nevertheless, the calculation of LV mass on the basis of two-dimensional and 
three-dimensional echocardiography is to be recommended, especially in 
deformed and/or remodeled ventricles.
75,107
 The assessment of LV outflow 
tract diameter for the calculation of forward stroke volume during exercise 
may sometimes be problematic, especially in repeated examinations. 
Therefore, the measurement of LV outflow tract diameter was performed only 
at rest and assumed not to change in response to exercise, as suggested by the 
American Society of Echocardiography.
76
 On the other hand, the assessment 
of LV stroke distance is recognized to be a simple, rapid, and reliable measure 
even in the context of a stress test and allows serial evaluations for multiple 
comparison.  
By design, the CPX score focuses primarily on the ventilator gas exchange 
response to exercise and does not include other clinical markers of risk in HF. 
There are other CPET responses that predict risk, particularly oscillatory 
breathing,
108, 109
 which were not included in the score. 
In this study, the confounding effect of cardiac medications on outcome was 
not considered. Finally, the number of patients included in this study was 
rather small for risk stratification; but, this was the first comprehensive study 
that tested the value of these new indices in patients with heart failure, and 
our findings are intended to be preliminary. 
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7  CONCLUSIONS 
 
None of the currently available variables for prognostic stratification of 
patients with HFrEF is sufficiently significative and, at the same time, none of 
these provides information on pump function of the heart under stress. 
Exercise stress echocardiography may endow with additional insights for 
prognostication of these patients.
75
 
PeakVO2 is considered the best CPET indicator of prognosis in patients with 
heart failure. Our study confirmed the important role of cardiopulmonary 
exercise testing peakVO2 in the prognostic stratification of patients with 
advanced HF. Subjects with a peakVO2 <14 ml/kg/min had a particularly 
impaired prognosis. However, the peak VO2 value depends not only on 
cardiovascular factors: many other pathological conditions (obesity, 
respiratory diseases, muscular diseases etc.)
98,99
 as well as cardiovascular 
deconditioning (poor fitness)
100 
can likewise lead to values in the CPET 
parameters, which overlap with those of patients with heart failure; in 
addiction it does not consider the influence of LV remodeling and provides 
only an indirect assessment of left ventricular exercise function.  
LV ejection fraction is the most frequently used index of cardiac function, but 
it may not accurately reflect myocardial contractility, and it provides little 
prognostic information in patients with advanced heart failure.  
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Echo-derived peak CPOM allows to evaluate the relationship between 
recruited myocardial muscle mass and the power of the left ventricle at 
maximum workload. It can give information about the rate at which potential 
energy stored in left ventricular mass is transformed into useful work. Dini 
and colleagues
85
 recently proved that CPOM is an independent predictor of 
outcome in patients with advanced HF and it is likely to reflect the LV 
morphological changes in maladaptive remodeling. In our study CPOM 
resulted to have the greater statistical significance in the prognostic 
stratification of patients with HFrEF. 
In order to ensure a correct and complete prognostic stratification of patients 
with HFrEF, which takes account of all aspects which we have discussed, the 
best option is to submit the subjects both to exercise echocardiography and 
cardiopulmonary test so as to combine their results and get a full metabolic 
and cardiorespiratory profile of the patients.  
In conclusion, this study demonstrate how the echo-parameter peak CPOM 
can represent a surplus value in the stratification of patients with HFrEF, in 
addition to the criteria that are classically used in these patients, as the 
ejection fraction or the NYHA class. Furthermore, when CPOM is combined 
with CPET parameters, the prognostic stratification of the patients results 
more accurate and complete.  
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